✦ LIBER ✦

Effect of duration of levodopa/decarboxylase inhibitor therapy on the pharmacokinetic handling of levodopa in elderly patients with idiopathic Parkinson's disease

✍ Scribed by S. G. Bowes; C. J. A. O'Neill; P. W. Nicholson; A. L. Leeman; A. A. Deshmukh; R. J. Dobbs; S. M. Dobbs

Publisher: Springer
Year: 1991
Tongue: English
Weight: 450 KB
Volume: 41
Category: Article
ISSN: 0031-6970
DOI: 10.1007/bf00626369

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of age on the pharmacokinetics of

Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease

✍ M. Contin; R. Riva; P. Martinelli; F. Albani; A. Baruzzi 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 436 KB

Effect of entacapone, a COMT inhibitor,

Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease

✍ V. V. Myllylä; K. A. Sotaniemi; A. Illi; K. Suominen; T. Keränen 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 563 KB

In an open, randomised, cross-over study we investigated the effect of a single 200 mg oral dose of entacapone, a novel catechol-O-methyltransferase (COMT) inhibitor, on the pharmacokinetics and metabolism of levodopa/carbidopa, and on the cardiovascular responses (blood pressure and pulse rate vari

Effects of levodopa and COMT inhibitors

Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients

✍ Paolo Lamberti; Stefano Zoccolella; Giovanni Iliceto; Elio Armenise; Angela Frad 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 1 views

## Abstract Homocysteine (Hcy) is a risk factor for vascular diseases, cognitive impairment, and dementia. Elevated plasma concentrations of Hcy have been found recently in Parkinson's disease (PD) patients treated with levodopa, suggesting that levodopa is a cause of hyperhomocysteinemia (HHcy). T

Effects of tolcapone, a catechol-O-methy

Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease

✍ M. Yamamoto; M. Yokochi; S. Kuno; Y. Hattori; Y. Tsukamoto; H. Narabayashi; H. T 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 517 KB

Levodopa alone and in combination with a

Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (madopar®) in the treatment of Parkinson's disease

✍ U. K. Rinne; E. Birket-Smith; E. Dupont; E. Hansen; M. Hyyppä; R. Marttila; B. M 📂 Article 📅 1975 🏛 Springer 🌐 English ⚖ 528 KB

A combination of levodopa and the extracerebrally acting decarboxylase inhibitor benserazide (ratio 4:1) (Madopar), was compared with levodopa alone in a controlled double-blind clinical multicenter trial on 94 patients with Parkinson's disease. During 4 months of therapy levodopa + benserazide prov

Randomized trial of tolcapone versus per

Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations

✍ William Koller; Andrew Lees; Miroslava Doder; Mariese Hely 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 1 views

## Abstract In this 12‐week, randomized, open‐label, blinded‐rater, parallel‐group trial, the efficacy, safety, and tolerability of tolcapone and pergolide were compared in parkinsonian patients with a fluctuating response to levodopa. Patients received tolcapone 100 mg three times daily (t.i.d.),